Pepbloc PK



Formulation : 2-Tosyl-(D,L)-homophenylalanin-4-amidinoanilid hydrochlorid

MW(Da) : 487 Pepbloc PK inhibits plasma kallikrein (PK) competitively and suppresses undesired cleavage of the substrate by plasma kallikrein.

Reference PresentationPackaging  
6-INH-PK-5Vial5 mg

The Safety Data Sheets and Notices are accessible to our registered customers.